Our Technologies

We are a clinical stage biopharmaceutical company focused on developing transformative medicines for the treatment of chronic vision-threatening diseases of the retina and optic nerve. Our proprietary ocular delivery technologies, which are designed to maintain potent and effective drug levels in ocular tissue for up to 12 months and potentially longer, will improve patient compliance, reduce healthcare burdens and ultimately improve clinical outcomes.